A Review of Newly Diagnosed Glioblastoma

Oronsky, Bryan; Reid, Tony; Oronsky, Arnold L.; Sandhu, Navjot; Knox, Susan J.

doi:10.3389/fonc.2020.574012

Cited by 88 publications

(91 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Brain glioblastoma multiforme (GBM) is the most common primary malignant intracranial tumor (50%), and is associated with high morbidity and mortality in both adults and children (1)(2)(3)(4). A histopathological from low-grade to high-grade transformation is associated with poor overall survival (5).…”

Section: Introductionmentioning

confidence: 99%

Identification of an IFN-β-associated gene signature for the prediction of overall survival among glioblastoma patients

Cheng¹,

Yuan²,

Li³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Background: Brain glioblastoma multiforme (GBM) is the most common primary malignant intracranial tumor. The prognosis of this disease is extremely poor. While the introduction of β-interferon (IFN-β) regimen in the treatment of gliomas has significantly improved the outcome of patients; The mechanism by which IFN-β induces increased TMZ sensitivity has not been described. Therefore, the main objective of the study was to elucidate the molecular mechanisms responsible for the beneficial effect of IFNβ in GBM.Methods: Messenger RNA expression profiles and clinicopathological data were downloaded from The Cancer Genome Atlas (TCGA) GBM and GSE83300 dataset from the Gene Expression Omnibus.Univariate Cox regression analysis and lasso Cox regression model established a novel 4-gene IFN-β signature (peroxiredoxin 1, Sec61 subunit beta, X-ray repair cross-complementing 5, and Bcl-2-like protein 2) for GBM prognosis prediction. Further, GBM samples (n=50) and normal brain tissues (n=50) were then used for real-time polymerase chain reaction experiments. Gene set enrichment analysis (GSEA) was performed to further understand the underlying molecular mechanisms. Pearson correlation was applied to calculate the correlation between the long non-coding RNAs (lncRNAs) and IFN-β-associated genes.An lncRNA with a correlation coefficient |R 2 |>0.3 and P<0.05 was considered to be an IFN-β-associated lncRNA.Results: Patients in the high-risk group had significantly poorer survival than patients in the low-risk group. The signature was found to be an independent prognostic factor for GBM survival. Furthermore, GSEA revealed several significantly enriched pathways, which might help explain the underlying mechanisms. Our study identified a novel robust 4-gene IFN-β signature for GBM prognosis prediction.The signature might contain potential biomarkers for metabolic therapy and treatment response prediction for GBM patients.Conclusions: In the present study, we established a novel IFN-β-associated gene signature to predict the overall survival of GBM patients, which may help in clinical decision making for individual treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of an IFN-β-associated gene signature for the prediction of overall survival among glioblastoma patients

Cheng¹,

Yuan²,

Li³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…The WHO classifies brain tumors into four groups (I–IV) of growing malignancy based on the morphological features of the tumor and their cells of origin [ 39 ]. Grades I and II include tumors with low proliferation potential, whereas grades III and IV tumors are high-grade gliomas characterized by high proliferation rates and aggressiveness [ 40 ]. GBM is classified as a grade IV high-speed growth tumor showing diffuse boundaries and is usually associated with a poor prognosis [ 6 ].…”

Section: Gbm Classificationmentioning

confidence: 99%

“…Overexpression of the CD133 marker in some GBM cells has been linked to poor prognosis since it leads to immune suppression by inducing T-cell apoptosis and upregulation of Treg cells [ 9 ]. Besides, GBM is a so-called immunological cold tumor showing low immunogenicity and an immunosuppressive microenvironment with low T lymphocyte infiltration [ 40 ]. Consequently, some immunotherapeutic strategies were evaluated to assess their potential use.…”

Section: Novel Therapeutic Strategies For Gbmmentioning

confidence: 99%

Adjusting the Molecular Clock: The Importance of Circadian Rhythms in the Development of Glioblastomas and Its Intervention as a Therapeutic Strategy

Wagner

Prucca

Caputto

et al. 2021

IJMS

View full text Add to dashboard Cite

Gliomas are solid tumors of the central nervous system (CNS) that originated from different glial cells. The World Health Organization (WHO) classifies these tumors into four groups (I–IV) with increasing malignancy. Glioblastoma (GBM) is the most common and aggressive type of brain tumor classified as grade IV. GBMs are resistant to conventional therapies with poor prognosis after diagnosis even when the Stupp protocol that combines surgery and radiochemotherapy is applied. Nowadays, few novel therapeutic strategies have been used to improve GBM treatment, looking for higher efficiency and lower side effects, but with relatively modest results. The circadian timing system temporally organizes the physiology and behavior of most organisms and daily regulates several cellular processes in organs, tissues, and even in individual cells, including tumor cells. The potentiality of the function of the circadian clock on cancer cells modulation as a new target for novel treatments with a chronobiological basis offers a different challenge that needs to be considered in further detail. The present review will discuss state of the art regarding GBM biology, the role of the circadian clock in tumor progression, and new chrono-chemotherapeutic strategies applied for GBM treatment.

show abstract

“…The WHO classified brain tumors into four groups (I-IV) of growing malignancy based on the morphological features of the tumor and its cell of origin [39]. Grade I and II include tumors with low proliferation potential, whereas grade III and IV tumors are high-grade gliomas characterized by high proliferation rates and aggressiveness [40]. GBM is classified as a grade IV high-speed growth tumor showing diffuse boundaries and is usually associated with a poor prognosis [6].…”

Section: Gbm Classificationmentioning

confidence: 99%

“…Overexpression of the CD133 marker in some GBM cells has been linked to poor prognosis since it leads to immune suppression by inducing T-cell apoptosis and upregulation of Treg cells [9]. Besides, GBM is a so-called immunological cold tumor showing low immunogenicity and an immunosuppressive microenvironment with low T lymphocyte infiltration [40]. Consequently, some immunotherapeutic strategies were evaluated to assess their potential use.…”

Section: Novel Therapeutic Strategies For Gbmmentioning

confidence: 99%

Adjusting the Clock: the Importance of Circadian Rhythms in the Development of Glioblastomas and Its Intervention as a Therapeutic Strategy

Wagner¹,

Prucca²,

Caputto³

et al. 2021

Preprint

View full text Add to dashboard Cite

Gliomas are solid tumors of the Central Nervous System (CNS) that originated from different glial cells. The World Health Organization (WHO) classified these tumors into four groups (I-IV) with increasing malignancy. Glioblastoma (GBM) is the most common and aggressive type of brain tumor classified as a grade IV. GBM are resistant to conventional therapies with poor prognosis after diagnosis even when the Stupp protocol that combines surgery and radiochemotherapy is applied. Nowadays, few novel therapeutic strategies have been used to improve GBM treatment, looking for higher efficiency and lower side effects, but with relatively modest results. The circadian timing system temporally organizes the physiology and behavior of most organisms and daily regulates several cellular processes in organs, tissues, and even in individual cells, including tumor cells. The potentiality of the function of the circadian clock on cancer cells modulation as a new target for novel treatments with a chronobiological basis offers a different challenge that needs to be considered in further detail. The present review will discuss state of the art regarding GBM biology, the role of the circadian clock in tumor progression, and new chrono-chemotherapeutic strategies applied for GBM treatment.

show abstract

A Review of Newly Diagnosed Glioblastoma

Cited by 88 publications

References 121 publications

Identification of an IFN-β-associated gene signature for the prediction of overall survival among glioblastoma patients

Identification of an IFN-β-associated gene signature for the prediction of overall survival among glioblastoma patients

Adjusting the Molecular Clock: The Importance of Circadian Rhythms in the Development of Glioblastomas and Its Intervention as a Therapeutic Strategy

Adjusting the Clock: the Importance of Circadian Rhythms in the Development of Glioblastomas and Its Intervention as a Therapeutic Strategy

Contact Info

Product

Resources

About